Weike Bio is a gene therapy drug development company. Its main business includes gene therapy insertion mutation risk assessment, high-precision crispr/cas9 quantitative off-target analysis, sgRNA screening, etc. The LTA-PCR and TES systems relied on are the first verified ISA detection methods in the world, and have completed a number of FDA and EMA approved gene therapy drug insertion mutation risk assessments. The company recently announced that it has completed tens of millions of angel round financing, with Huada Win-Win as the exclusive investment. This round of financing will help Vico Bio to accelerate technology upgrades and team building, promote the expansion of testing services such as the cell gene therapy industry, the safety assessment of the gene editing and breeding industry, and the automation of laboratory platforms.
This article is transferred from: https://www.itjuzi.com/investevent/13731645
This site is only for collection, and the copyright belongs to the original author.